Abstract
Resolvins, belonging to the group of specialized proresolving mediators (SPMs), are metabolic products of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) and are synthesized during the initial phases of acute inflammatory responses to promote the resolution of inflammation. Resolvins are produced for termination of neutrophil infiltration, stimulation of the clearance of apoptotic cells by macrophages, and promotion of tissue remodeling and homeostasis. Metabolic dysregulation due to either uncontrolled activity of pro-inflammatory responses or to inefficient resolution of inflammation results in chronic inflammation and may also lead to atherosclerosis or other chronic autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus, vasculitis, inflammatory bowel diseases, and type 1 diabetes mellitus. The pathogenesis of such diseases involves a complex interplay between the immune system and, environmental factors (non-infectious or infectious), and critically depends on individual susceptibility to such factors. In the present review, resolvins and their roles in the resolution of inflammation, as well as the role of these mediators as potential therapeutic agents to counteract specific chronic autoimmune and inflammatory diseases are discussed.
Similar content being viewed by others
References
Kumar V, Abbas AK, Fausto N, Aster JC (2014) Robbins and Cotran pathologic basis of disease, professional edition e-book. elsevier health sciences
Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135–1143
Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6(7):508–519
Serhan CN, Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111(10):5922–5943. https://doi.org/10.1021/cr100396c
Majno G, Joris I (2004) Cells, tissues, and disease: principles of general pathology. Oxford University Press
Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, Perretti M, Rossi AG, Wallace JL (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21(2):325–332
Serhan CN (2004) A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol 122(4):305–321
Serhan CN, Ward PA, Gilroy DW (2010) Fundamentals of inflammation. Cambridge University Press
Schwab JM, Serhan CN (2006) Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 6(4):414–420
Crean D, Godson C (2015) Specialised lipid mediators and their targets. In: Seminars in immunology, vol 3. Elsevier, pp 169–176
Samuelsson B, Dahlen S-E, Lindgren JA, Rouzer CA, Serhan CN (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237(4819):1171–1176
Manfredi AA, Ramirez GA, Rovere-Querini P, Maugeri N (2018) The neutrophil’s choice: phagocytose vs make neutrophil extracellular traps. Front Immunol 9:288
Branzk N, Lubojemska A, Hardison SE, Wang Q, Gutierrez MG, Brown GD, Papayannopoulos V (2014) Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol 15(11):1017–1025
Warnatsch A, Tsourouktsoglou T-D, Branzk N, Wang Q, Reincke S, Herbst S, Gutierrez M, Papayannopoulos V (2017) Reactive oxygen species localization programs inflammation to clear microbes of different size. Immunity 46(3):421–432
McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P (2012) Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 12(3):324–333
Kim S-J, Jenne CN (2016) Role of platelets in neutrophil extracellular trap (NET) production and tissue injury. In: Seminars in immunology, vol 6. Elsevier, pp 546–554
Chiurchiù V, Leuti A, Dalli J, Jacobsson A, Battistini L, Maccarrone M, Serhan CN (2016) Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci Transl Med 8(353):353ra111
Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2(7):612–619
Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201(5):713–722. https://doi.org/10.1084/jem.20042031
Chiang N, Fredman G, Bäckhed F, Oh SF, Vickery T, Schmidt BA, Serhan CN (2012) Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484(7395):524–528
Han CZ, Ravichandran KS (2011) Metabolic connections during apoptotic cell engulfment. Cell 147(7):1442–1445
Köröskényi K, Duró E, Pallai A, Sarang Z, Kloor D, Ucker DS, Beceiro S, Castrillo A, Chawla A, Ledent CA (2011) Involvement of adenosine A2A receptors in engulfment-dependent apoptotic cell suppression of inflammation. J Immunol 1002284
Serhan CN, Chiang N (2013) Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13(4):632–640
Dalli J, Winkler JW, Colas RA, Arnardottir H, Cheng C-YC, Chiang N, Petasis NA, Serhan CN (2013) Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol 20(2):188–201
Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447(7146):869–874
Spite M, Serhan CN (2010) Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 107(10):1170–1184
Nathan C (2002) Points of control in inflammation. Nature 420(6917):846–852
Back M, Yurdagul A Jr, Tabas I, Oorni K, Kovanen PT (2019) Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 16:389–406. https://doi.org/10.1038/s41569-019-0169-2
Serhan CN (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101–137. https://doi.org/10.1146/annurev.immunol.25.022106.141647
Bannenberg G, Serhan CN (2010) Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 1801(12):1260–1273. https://doi.org/10.1016/j.bbalip.2010.08.002
Serhan CN (2010) Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 177(4):1576–1591. https://doi.org/10.2353/ajpath.2010.100322
Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, Colgan SP, Petasis NA, Serhan CN (2007) Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 282(13):9323–9334. https://doi.org/10.1074/jbc.M609212200
Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461(7268):1287–1291. https://doi.org/10.1038/nature08541
Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN (2005) Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102(21):7671–7676. https://doi.org/10.1073/pnas.0409271102
Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192(8):1197–1204
Fetterman JW Jr, Zdanowicz MM (2009) Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 66(13):1169–1179. https://doi.org/10.2146/ajhp080411
Simopoulos AP (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21(6):495–505
Harper CR, Jacobson TA (2001) The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 161(18):2185–2192
Herrera BS, Hasturk H, Kantarci A, Freire MO, Nguyen O, Kansal S, Van Dyke TE (2015) Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. Infect Immun 83(2):792–801
Herová M, Schmid M, Gemperle C, Hersberger M (2015) ChemR23, the receptor for chemerin and resolvin E1, is expressed and functional on M1 but not on M2 macrophages. J Immunol 1402166
Seki H, Fukunaga K, Arita M, Arai H, Nakanishi H, Taguchi R, Miyasho T, Takamiya R, Asano K, Ishizaka A (2010) The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol 184(2):836–843
El Kebir D, Gjorstrup P, Filep JG (2012) Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci 201206641
Hong S, Porter TF, Lu Y, Oh SF, Pillai PS, Serhan CN (2008) Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol 180(5):3512–3519
Titos E, Rius B, González-Périz A, López-Vicario C, Morán-Salvador E, Martínez-Clemente M, Arroyo V, Clària J (2011) Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 1100225
Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510(7503):92–101
Kohli P, Levy BD (2009) Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol 158(4):960–971
Mogensen TH (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22(2):240–273
Akagi D, Chen M, Toy R, Chatterjee A, Conte MS (2015) Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J 29(6):2504–2513
Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee C-H, Yang R, Petasis NA, Serhan CN (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci 107(4):1660–1665
Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN (2012) Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol 180(5):2018–2027
Park C-K, Xu Z-Z, Liu T, Lü N, Serhan CN, Ji R-R (2011) Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J Neurosci 31(50):18433–18438
Wang B, Gong X, J-y W, Zhang L, Zhang Z, Li H-z, Min S (2011) Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm Pharmacol Ther 24(4):434–441
Liao Z, Dong J, Wu W, Yang T, Wang T, Guo L, Chen L, Xu D, Wen F (2012) Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway. Respir Res 13(1):110
Wang L, Wang FS, Gershwin ME (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278(4):369–395
Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN (2007) TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13(5):543–551
Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, Petasis NA, Erwig L, Rees AJ, Savill J (2002) Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 13(10):2497–2507
Milligan G, Stoddart LA, Brown AJ (2006) G protein-coupled receptors for free fatty acids. Cell Signal 18(9):1360–1365. https://doi.org/10.1016/j.cellsig.2006.03.011
Eizirik DL, Colli ML, Ortis F (2009) The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat Rev Endocrinol 5(4):219–226
Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R-L (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196(8):1025–1037
Chiang N, Arita M, Serhan CN (2005) Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fat Acids 73(3–4):163–177
Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142(5):687–698
Das UN (2011) Lipoxins as biomarkers of lupus and other inflammatory conditions. Lipids Health Dis 10:76. https://doi.org/10.1186/1476-511x-10-76
Lattin JE, Schroder K, Su AI, Walker JR, Zhang J, Wiltshire T, Saijo K, Glass CK, Hume DA, Kellie S, Sweet MJ (2008) Expression analysis of G protein-coupled receptors in mouse macrophages. Immunome Res 4:5. https://doi.org/10.1186/1745-7580-4-5
Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC (2007) Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis 13(6):797–799. https://doi.org/10.1002/ibd.20109
Kelsall BL, Leon F (2005) Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. Immunol Rev 206:132–148. https://doi.org/10.1111/j.0105-2896.2005.00292.x
Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, Dignass AU (2005) Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut 54(2):228–236. https://doi.org/10.1136/gut.2004.040360
Allen B (1991) Fish oil in combination with other therapies in the treatment of psoriasis. In: Health effects of omega 3 polyunsaturated fatty acids in seafoods, vol 66. Karger Publishers, pp 436–445
Cleland L, James M (1997) Rheumatoid arthritis and the balance of dietary N-6 and N-3 essential fatty acids. Br J Rheumatol 36(5):513–514
Kremer JM (2000) N-3 fatty acid supplements in rheumatoid arthritis. Am J Clin Nutr 71(1 Suppl):349s–351s. https://doi.org/10.1093/ajcn/71.1.349s
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380(1):11–22
Hughes RA, Cornblath DR (2005) Guillain-Barre syndrome. Lancet (London, England) 366(9497):1653–1666. https://doi.org/10.1016/s0140-6736(05)67665-9
Soliven B (2012) Autoimmune neuropathies: insights from animal models. J Peripher Nerv Syst 17:28–33
Yun JH, Henson PM, Tuder RM (2008) Phagocytic clearance of apoptotic cells: role in lung disease. Exp Rev Respir Med 2(6):753–765. https://doi.org/10.1586/17476348.2.6.753
Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S (2008) The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol 20(11):1361–1368. https://doi.org/10.1093/intimm/dxn106
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101(4):890–898
Kimura A, Naka T, Kishimoto T (2007) IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci 104(29):12099–12104. https://doi.org/10.1073/pnas.0705268104
Luchting B, Rachinger-Adam B, Heyn J, Hinske LC, Kreth S, Azad SC (2015) Anti-inflammatory T-cell shift in neuropathic pain. J Neuroinflammation 12:12. https://doi.org/10.1186/s12974-014-0225-0
Zhang Z, Zhang ZY, Schluesener HJ (2009) Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 183(5):3081–3091. https://doi.org/10.4049/jimmunol.0901088
Luo B, Han F, Xu K, Wang J, Liu Z, Shen Z, Li J, Liu Y, Jiang M, Zhang ZY, Zhang Z (2016) Resolvin D1 programs inflammation resolution by increasing TGF-beta expression induced by dying cell clearance in experimental autoimmune neuritis. J Neurosci 36(37):9590–9603. https://doi.org/10.1523/jneurosci.0020-16.2016
Dhopeshwarkar A, Mackie K (2014) CB2 cannabinoid receptors as a therapeutic target—what does the future hold? Mol Pharmacol 86(4):430–437
Rom S, Persidsky Y (2013) Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J NeuroImmune Pharmacol 8(3):608–620
Turcotte C, Blanchet M-R, Laviolette M, Flamand N (2016) The CB 2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci 73(23):4449–4470
Tepper MA, Zurier RB, Burstein SH (2014) Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. Bioorg Med Chem 22(13):3245–3251
Motwani MP, Bennett F, Norris PC, Maini AA, George MJ, Newson J, Henderson A, Hobbs AJ, Tepper M, White B (2018) Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation. Clin Pharmacol Ther 104(4):675–686
Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH (1998) Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 41(1):163–170
Zurier RB, Sun Y-P, George KL, Stebulis JA, Rossetti RG, Skulas A, Judge E, Serhan CN (2009) Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J 23(5):1503–1509
Gonzalez EG, Selvi E, Balistreri E, Akhmetshina A, Palumbo K, Lorenzini S, Lazzerini PE, Montilli C, Capecchi PL, Lucattelli M (2012) Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis 71(9):1545–1551
Lucattelli M, Fineschi S, Selvi E, Gonzalez EG, Bartalesi B, De Cunto G, Lorenzini S, Galeazzi M, Lungarella G (2016) Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung. Respir Res 17(1):49
Abdolmaleki F, Farahani N, Gheibi Hayat SM, Pirro M, Bianconi V, Barreto GE, Sahebkar A (2018) The role of efferocytosis in autoimmune diseases. Front Immunol 9:1645. https://doi.org/10.3389/fimmu.2018.01645
Gheibi Hayat SM, Bianconi V, Pirro M, Sahebkar A (2019) Efferocytosis: molecular mechanisms and pathophysiological perspectives. Immunol Cell Biol 97(2):124–133. https://doi.org/10.1111/imcb.12206
Tajbakhsh A, Gheibi Hayat SM, Butler AE, Sahebkar A (2019) Effect of soluble cleavage products of important receptors/ligands on efferocytosis: their role in inflammatory, autoimmune and cardiovascular disease. Ageing Res Rev 50:43–57. https://doi.org/10.1016/j.arr.2019.01.007
Tajbakhsh A, Rezaee M, Kovanen PT, Sahebkar A (2018) Efferocytosis in atherosclerotic lesions: malfunctioning regulatory pathways and control mechanisms. Pharmacol Ther 188:12–25. https://doi.org/10.1016/j.pharmthera.2018.02.003
Lauber K, Blumenthal SG, Waibel M, Wesselborg S (2004) Clearance of apoptotic cells: getting rid of the corpses. Mol Cell 14(3):277–287
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed Consent
No informed consent was required to prepare the manuscript.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Abdolmaleki, F., Kovanen, P.T., Mardani, R. et al. Resolvins: Emerging Players in Autoimmune and Inflammatory Diseases. Clinic Rev Allerg Immunol 58, 82–91 (2020). https://doi.org/10.1007/s12016-019-08754-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-019-08754-9